X4 Pharmaceuticals Inc’s filing revealed that its Chief Financial Officer Mostafa Adam S. unloaded Company’s shares for reported $46347.0 on Mar 11 ’24. In the deal valued at $0.88 per share,52,500 shares were sold. As a result of this transaction, Mostafa Adam S. now holds 0 shares worth roughly $0.0.
Then, Ragan Paula sold 49,678 shares, generating $43,856 in total proceeds. Upon selling the shares at $0.88, the President and CEO now owns 765,068 shares.
Before that, DiBiase Mary sold 15,409 shares. X4 Pharmaceuticals Inc shares valued at $13,591 were divested by the Chief Operating Officer at a price of $0.88 per share. As a result of the transaction, DiBiase Mary now holds 291,752 shares, worth roughly $0.4 million.
B. Riley Securities downgraded its X4 Pharmaceuticals Inc [XFOR] rating to a Neutral from a a Buy in a research note published on December 12, 2023; the price target was decreased to $1 from $3. Cantor Fitzgerald began covering XFOR with “an Overweight” recommendation on December 22, 2022. Piper Sandler started covering the stock on December 12, 2022. It rated XFOR as “an Overweight”.
Price Performance Review of XFOR
On Monday, X4 Pharmaceuticals Inc [NASDAQ:XFOR] saw its stock jump 7.94% to $1.36. Over the last five days, the stock has gained 8.80%. X4 Pharmaceuticals Inc shares have risen nearly 62.19% since the year began. While a 52-week high of $2.58 was reached on 04/03/24, a 52-week low of $0.57 was recorded on 01/25/24. SMA at 50 days reached $1.1133, while 200 days put it at $1.0731. A total of 2.43 million shares were traded, compared to the trading of 1.73 million shares in the previous session.
Levels Of Support And Resistance For XFOR Stock
The 24-hour chart illustrates a support level at 1.2533, which if violated will result in even more drops to 1.1467. On the upside, there is a resistance level at 1.4133. A further resistance level may holdings at 1.4667. The Relative Strength Index (RSI) on the 14-day chart is 57.94, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0302, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 45.28%. Stochastics %K at 38.36% indicates the stock is a holding.
The most recent change occurred on December 23, 2019 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $20 price target.
